What is MSM?
MSM (methylsulfonylmethane) is an organic sulfur compound that occurs naturally in small amounts in foods like cruciferous vegetables, onions, garlic, and certain grains. It has become increasingly featured in joint health, recovery, and general wellness supplements, often positioned as a collagen-supporting nutrient. The compound contains approximately 34% elemental sulfur by weight, which is frequently emphasized in marketing. While the body does utilize sulfur in collagen and connective tissue synthesis, MSM’s specific role in endogenous sulfur metabolism remains incompletely characterized and often overstated in promotional contexts.
The Core Evidence: Joint Health
The most consistent research focus involves joint-related outcomes, particularly osteoarthritis symptoms. The 2006 Kim et al. RCT randomized participants with knee osteoarthritis to MSM or placebo and found modest improvements in joint pain and function measured via WOMAC scores (Western Ontario and McMaster Universities Arthritis Index). Effect sizes were small to moderate, and the sample was relatively small, limiting generalizability. Critically, the study was only 12 weeks in duration, so durability of any benefits remains uncertain.
Several other trials have examined MSM in joint contexts with heterogeneous results. Some show benefit; others show no clear advantage over placebo when expectancy effects are properly controlled. The variability in study design, dosing regimens (typically 500 mg to 3,000 mg daily), study duration, and outcome measures makes systematic meta-analysis difficult. A 2019 systematic review concluded that while MSM shows promise for osteoarthritis symptom relief, the evidence base remains relatively small and of modest methodological quality—most studies lack rigorous randomization procedures, blinding verification, or intention-to-treat analysis.
Inflammation and Recovery Claims
The 2012 Kalman et al. study explored MSM in exercise recovery and inflammatory markers. Participants taking MSM showed some reduction in muscle soreness and inflammatory cytokines (TNF-α, IL-6) compared to placebo, but effect sizes were modest and statistical power was limited by sample size. The study was conducted in trained athletes, so applicability to sedentary or general populations is uncertain and should not be assumed.
Claims about MSM’s anti-inflammatory properties often cite its sulfur content and theoretical benefits for connective tissue, but direct human evidence demonstrating clinically meaningful reductions in systemic inflammation is limited. In vitro studies suggest MSM can inhibit certain inflammatory pathways (NF-κB signaling), but this does not reliably translate to meaningful in vivo effects at typical supplemental doses in humans. The gap between test-tube biology and real-world efficacy remains substantial and is frequently glossed over in marketing.
Safety: A Genuine Strength
The 2017 Butawan et al. review examined MSM’s safety profile and concluded it is generally well-tolerated at standard doses. Reported adverse effects are rare and mild, typically limited to minor gastrointestinal symptoms (nausea, diarrhea), transient skin reactions, or headache. Serious adverse events have not been documented in the clinical literature at recommended supplemental doses, which is genuinely reassuring. This favorable safety profile is one of MSM’s genuine strengths—it appears to have a low toxicity ceiling and minimal drug interaction potential.
However, tolerability at higher doses (>5 g daily) or in susceptible populations (severe liver or kidney disease) has not been extensively studied. As with most supplements, pregnant or breastfeeding women should avoid supplementation due to insufficient safety data rather than documented harm.
Regulatory Context: What EFSA’s Silence Means
The European Food Safety Authority (EFSA) has not approved any health claims for MSM relating to joints, inflammation, tissue repair, or collagen support. This reflects that the evidence presented to EFSA did not meet the threshold for substantiation under the strict Nutrition and Health Claims Regulation (EC 1924/2006). This does not mean MSM is ineffective, but rather that its effects, if present, are modest and difficult to standardize and reproduce across diverse populations. EFSA’s position is evidence-based, not arbitrary, and should inform realistic expectations.
Practical Expectations and Realistic Assessment
What MSM might plausibly do: Provide small to modest improvements in joint comfort in people with existing osteoarthritis or chronic joint complaints. Possibly contribute to recovery optimization from intense exercise. Serve as one sulfur source among many for normal collagen synthesis.
What MSM probably won’t do: Reverse osteoarthritis, cure inflammatory disorders, dramatically accelerate muscle recovery compared to sleep and nutrition, prevent joint damage, or serve as a universal joint health panacea. Produce noticeable benefits in healthy young individuals without existing joint issues.
Evidence quality assessment: Level 3 (weak). There are human trials, but most are small, short-term, and conducted by researchers or institutions with financial interests in supplement sales. Effect sizes range from small to moderate, with high heterogeneity between studies. Publication bias toward positive results is likely, as negative studies often remain unpublished.
Dosing and Practical Considerations
Clinical studies typically used 500–3,000 mg daily, divided into multiple doses. MSM dissolves readily in water and is rapidly absorbed, so there is no strong scientific rationale for particular timing relative to meals. It can be taken with meals or on an empty stomach, though gastric tolerance may be slightly better with food. Onset of potential benefits, if they materialize, typically requires weeks to months of consistent use—this is not a compound for acute symptom relief or rapid improvements.
Who Might Plausibly Benefit?
MSM is most defensibly beneficial for individuals with chronic knee osteoarthritis or similar joint complaints who are seeking a low-risk, non-prescription complementary option. It would be reasonable as part of a comprehensive strategy alongside evidence-based therapies (physical therapy, weight management, appropriate pain management, and potentially collagen peptides or glucosamine sulfate). It is less clearly beneficial for young, healthy individuals seeking preventive supplementation without existing joint problems.
Athletes interested in recovery support might see marginal benefits on the order of 5–10% improvement in soreness, but evidence for this use case is weaker than for joint health, and the magnitude of effect is unlikely to justify consistent cost and adherence unless already committed to comprehensive recovery optimization including sleep and nutrition optimization.
Final Assessment
MSM is solid but unremarkable. It is well-tolerated, relatively inexpensive, and has some research support for joint-related benefits in specific populations. However, the effects are modest at best, the evidence base is small relative to marketing claims, and it is not a substitute for established evidence-based therapies for osteoarthritis. Marketing frequently and significantly overstates its capabilities. It is a reasonable, low-risk addition to a joint health regimen but not a cornerstone or solution in itself.